Executive Summary ReVasc Corporation Inc., ("ReVasc"), a Delaware corporation, was formed to simplify, make more effective, and reduce the risk attendant to the treatment of Abdominal Aortic Aneurysms ("AAA"). ReVasc has unique technology anchored in issued and pending patents. The Problem The open AAA surgery itself, regardless of method, is a traumatic procedure carrying with it high mortality rates. Moreover, the available stent-grafts deform, "pucker" and "travel" leading to procedure failure (no seal) and AAA rupture. The Challenge Repair abdominal aortic aneurysms percutaneously. ReVasc's Solution Deploy a unique, low profile, pliable stent, percutaneously. The Potential Market Rapidly approaching One Billion Dollars a year. (NationsBanc Montgomery Securities estimates the worldwide market for AAA stent-grafts to be over $300,000,000 with a 2002 worldwide market of close to $700,000,000. These numbers are, in fact, modest in light of the fact that as of 2000 less than 15% of all AAA cases are diagnosed and of those less than 10% are stented). The State-of-the-Art Abdominal aortic aneurysms affect roughly 1.5 million Americans, yet only a small portion of those are ever diagnosed. Absent immediate successful treatment, a ruptured abdominal aorta is fatal. The conventional treatment for AAA is surgery. But this surgery is extremely high risk and carries with it a high mortality. Stenting (using stents covered with a graft material) somewhat reduces the mortality rate and shortens the time of the procedure from an average five hours to only two. Present day stenting, using state-of-the-art stents, is problematic because of: Perigraft leakage, which occurs when the neck of the aneurysm dilates beyond the neck of the stent graft; Graft material fatigue, which is caused by the continuous flexing and stresses that occur over the life of a stent; Backflow from the lumbar arteries; and, The range of sizes and shapes among patients aneurysms. The ReVasc Device ReVasc has created a unique stent for AAA. One of Revasc's devices, The ReVasc "Full-Motion™" Stent uses an advanced and unique design, which allows for a very low profile and for accommodation of torque forces and rotational pressures. The ReVasc Full-Motion Stent grows, shrinks, moves and rotates with the aneurysm. It beats the aneurysm by accommodating it, not by fighting it. Where most all other stent grafts seek to address the problem of change in aneurysm size, shape and direction by force, the ReVasc Full Motion Stent does so by smart design. Another ReVasc device, the ReVasc "Weave™" stent, employs unique materials to bridge the aneurysm. First generation ReVasc stents have been tested in humans in the United States under compassionate use exemptions and have performed exceptionally well. Animal studies are underway at several clinical sites. Back to Portfolio Page